Arcutis Biotherapeutics (ARQT) Stock Forecast, Price & News

Arcutis Biotherapeutics (NASDAQ:ARQT) Frequently Asked Questions

Is Arcutis Biotherapeutics a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arcutis Biotherapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Arcutis Biotherapeutics stock.
View analyst ratings for Arcutis Biotherapeutics or view top-rated stocks.

When is Arcutis Biotherapeutics' next earnings date?

Arcutis Biotherapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Arcutis Biotherapeutics.

How were Arcutis Biotherapeutics' earnings last quarter?

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) released its quarterly earnings results on Thursday, May, 5th. The company reported ($1.27) earnings per share for the quarter, beating analysts' consensus estimates of ($1.50) by $0.23.
View Arcutis Biotherapeutics' earnings history.

What price target have analysts set for ARQT?

4 equities research analysts have issued 1-year target prices for Arcutis Biotherapeutics' stock. Their forecasts range from $37.00 to $57.00. On average, they anticipate Arcutis Biotherapeutics' stock price to reach $46.33 in the next year. This suggests a possible upside of 125.8% from the stock's current price.
View analysts' price targets for Arcutis Biotherapeutics or view top-rated stocks among Wall Street analysts.

Who are Arcutis Biotherapeutics' key executives?

Arcutis Biotherapeutics' management team includes the following people:

• Mr. Todd Franklin Watanabe M.A., Pres, CEO & Director (Age 54, Pay $940.2k) (LinkedIn Profile)
• Dr. Bhaskar Chaudhuri Ph.D., Co-Founder & Independent Director (Age 67, Pay $60.58k) (LinkedIn Profile)
• Mr. Scott L. Burrows, CFO & Principal Accounting Officer (Age 45, Pay $617.87k) (LinkedIn Profile)
• Dr. David W. Osborne Ph.D., Chief Technical Officer (Age 61, Pay $584.55k)
• Dr. Patrick E. Burnett M.D., Ph.D., Sr. VP & Chief Medical Officer (Age 50, Pay $700.1k)
• Mr. Matthew Richard Moore, Sr. VP & Chief Bus. Officer (Age 48, Pay $560.07k)
• Ms. Patricia A. Turney, Sr. VP of Operations (Age 55) (LinkedIn Profile)
• Mr. Eric McIntyre, Head of Investor Relations
• Ms. Courtney Barton, Chief Compliance Officer, VP, Chief of Staff & Chief Privacy Officer (Age 39)
• Mr. Masaru Matsuda Esq., J.D., Sr. VP, Gen. Counsel & Corp. Sec. (Age 51)

Who are some of Arcutis Biotherapeutics' key competitors?

Some companies that are related to Arcutis Biotherapeutics include Arrowhead Pharmaceuticals (ARWR), Galapagos (GLPG), Cerevel Therapeutics (CERE), Zai Lab (ZLAB), Bausch Health Companies (BHC), CureVac (CVAC), Mirati Therapeutics (MRTX), Ultragenyx Pharmaceutical (RARE), Blueprint Medicines (BPMC), Cytokinetics (CYTK), Karuna Therapeutics (KRTX), Pacira BioSciences (PCRX), ACADIA Pharmaceuticals (ACAD), Prestige Consumer Healthcare (PBH) and Indivior (INVVY).
View all of ARQT's competitors.

What other stocks do shareholders of Arcutis Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcutis Biotherapeutics investors own include Black Diamond Therapeutics (BDTX), Pfizer (PFE), Akero Therapeutics (AKRO), Advanced Micro Devices (AMD), Applied Therapeutics (APLT), Aptinyx (APTX), BioNTech (BNTX), ServiceNow (NOW), Qualys (QLYS) and AbbVie (ABBV).

When did Arcutis Biotherapeutics IPO?

(ARQT) raised $125 million in an IPO on Friday, January 31st 2020. The company issued 7,800,000 shares at $15.00-$17.00 per share. Goldman Sachs, Cowen and Guggenheim Securities served as the underwriters for the IPO and Cantor was co-manager.

What is Arcutis Biotherapeutics' stock symbol?

Arcutis Biotherapeutics trades on the NASDAQ under the ticker symbol "ARQT."

Who are Arcutis Biotherapeutics' major shareholders?

Arcutis Biotherapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Frazier Life Sciences Management L.P. (16.40%), BlackRock Inc. (8.39%), Vanguard Group Inc. (2.98%), State Street Corp (2.31%), American Century Companies Inc. (1.02%) and Ensign Peak Advisors Inc (0.96%). Company insiders that own Arcutis Biotherapeutics stock include Bhaskar Chaudhuri, David W Osborne, Howard G Welgus, Howard G Welgus, John W Smither, Orbimed Advisors Llc, Patricia A Turney, Patrick Burnett, Scott L Burrows and Todd Franklin Watanabe.
View institutional ownership trends for Arcutis Biotherapeutics.

Which institutional investors are selling Arcutis Biotherapeutics stock?

ARQT stock was sold by a variety of institutional investors in the last quarter, including Citigroup Inc., Sectoral Asset Management Inc., Northern Trust Corp, Walleye Capital LLC, Metropolitan Life Insurance Co NY, Royal Bank of Canada, California State Teachers Retirement System, and ProShare Advisors LLC. Company insiders that have sold Arcutis Biotherapeutics company stock in the last year include Bhaskar Chaudhuri, David W Osborne, Howard G Welgus, Orbimed Advisors Llc, Patricia A Turney, Patrick Burnett, Scott L Burrows, and Todd Franklin Watanabe.
View insider buying and selling activity for Arcutis Biotherapeutics or view top insider-selling stocks.

Which institutional investors are buying Arcutis Biotherapeutics stock?

ARQT stock was acquired by a variety of institutional investors in the last quarter, including Frazier Life Sciences Management L.P., GW&K Investment Management LLC, Dimensional Fund Advisors LP, Ensign Peak Advisors Inc, 1492 Capital Management LLC, State Street Corp, Hsbc Holdings PLC, and American Century Companies Inc..
View insider buying and selling activity for Arcutis Biotherapeutics or or view top insider-buying stocks.

How do I buy shares of Arcutis Biotherapeutics?

Shares of ARQT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arcutis Biotherapeutics' stock price today?

One share of ARQT stock can currently be purchased for approximately $20.52.

How much money does Arcutis Biotherapeutics make?

Arcutis Biotherapeutics has a market capitalization of $1.06 billion. The company earns $-206.36 million in net income (profit) each year or ($4.670010) on an earnings per share basis.

How many employees does Arcutis Biotherapeutics have?

Arcutis Biotherapeutics employs 147 workers across the globe.

What is Arcutis Biotherapeutics' official website?

The official website for Arcutis Biotherapeutics is www.arcutis.com.

How can I contact Arcutis Biotherapeutics?

Arcutis Biotherapeutics' mailing address is 2945 TOWNSGATE ROAD SUITE 110, WESTLAKE VILLAGE CA, 91361. The company can be reached via phone at 805-418-5006 or via email at [email protected].